Switching From Dupilumab to Tralokinumab or Janus Kinase Inhibitors in Cases of Ocular and/or Facial Adverse Events in Patients With Atopic Dermatitis: A Multicenter Retrospective Study

Post time Half hour(s) ago

journal：The Journal of Allergy and Clinical Immunology: In Practice

Authors：Alexandre Beyrouti; Juliette Deuze; Eric Fontas; Aurore Foureau; Sébastien Barbarot; Hélène Aubert; Claire Bernier; Marie Le Moigne; Thierry Passeron; Feriel Boukari; Margaux Garnier; Marie Jachiet; Florence Tetart; Julien Seneschal; Clémentine Toussaint; Emmanuel Mahé; Camille Leleu; Marie Masson Regnault; Justine Pasteur; Audrey Nosbaum; Antoine Badaoui; Anne-Claire Fougerousse; Pauline Pralong; Manuelle Viguier; Catherine Droitcourt; Claire Abasq; Stéphanie Mallet; Nadia Raison-Peyron; Delphine Staumont-Sallé; Thomas Hubiche

Published date：2025-2-

DOI：10.1016/j.jaip.2024.12.001

PDF link：https://www.sciencedirect.com/sc ... 213219824012418/pdf

Article link：https://doi.org/10.1016/j.jaip.2024.12.001

Article Source：Elsevier BV。

Remark：

Post time Half hour(s) ago

: This post has been completed
Completed attachments will be deleted within 24 hours.

[Elsevier] Switching From Dupilumab to Tralokinumab or Janus Kinase Inhibitors in Cases of Ocular and/or Facial Adverse Events in Patients With Atopic Dermatitis: A Multicenter Retrospective Study

Best Answer

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Elsevier] Switching From Dupilumab to Tralokinumab or Janus Kinase Inhibitors in Cases of Ocular and/or Facial Adverse Events in Patients With Atopic Dermatitis: A Multicenter Retrospective Study Copy

Best Answer

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Elsevier] Switching From Dupilumab to Tralokinumab or Janus Kinase Inhibitors in Cases of Ocular and/or Facial Adverse Events in Patients With Atopic Dermatitis: A Multicenter Retrospective Study